title: TLC characterization of liposomes containing angiotensinogen, angiotensine I, angiotensine II and saralazin.
abstract: Recent studies have described intracellular binding sites for angiotensine II. In vascular smooth muscle it was found that intracellular injection of angiotensin II increases the Ca2+ level. An alternative method for intracellular delivery of drugs is represented by using liposomes. Thus, the aim of this study was to characterize liposomes filled with angiotensinogen, angiotensine I (Ang I), angiotensine II (Ang II), and saralasin by a TLC method and examine the physiological effects of these on rat vascular smooth muscle. Ang II (for all concentrations tested in the aqueous phase) and Ang I (for concentrations less than 10(-4)M) did not affect the thin-layer chromatography migration of this type of vesicle, suggesting that dose-dependent effects on physio-pharmacological experiments could be studied. On the other hand, this type of experiment could not be performed for salarasin- or angiotensinogen-filled liposomes. Administration of liposomes containing Ang II (10(-6)M), Ang I (10(-6)M), angiotensinogen (10(-6)M) and saralasine (10(-6)M) caused the contraction to isolated rat aorta smooth muscle, suggesting the presence of active intracellular binding sites.
authors.affiliation: Department of Physiology, University of Medicine and Pharmacy Gr. T. Popa, Iasi, Romania.
authors.forename: E
authors.initials: E
authors.lastname: Brailoiu
authors.forename: M
authors.initials: M
authors.lastname: Todiras
authors.forename: A
authors.initials: A
authors.lastname: Margineanu
authors.forename: M
authors.initials: M
authors.lastname: Costuleanu
authors.forename: C
authors.initials: C
authors.lastname: Brailoiu
authors.forename: C
authors.initials: C
authors.lastname: Filipeanu
authors.forename: A
authors.initials: A
authors.lastname: Costuleanu
authors.forename: V
authors.initials: V
authors.lastname: Rusu
authors.forename: G
authors.initials: G
authors.lastname: Petrescu
mesh_terms: D000803:Angiotensin I / Q000032:analysis; D000804:Angiotensin II / Q000032:analysis; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000032:analysis*; D000808:Angiotensinogen / Q000032:analysis; D000809:Angiotensins / Q000032:analysis*; D000818:Animals; D002855:Chromatography, Thin Layer / Q000379:methods*; D008081:Liposomes / Q000737:chemistry; D008297:Male; D051381:Rats; D017208:Rats, Wistar; D012504:Saralasin / Q000032:analysis*
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000809:Angiotensins; D008081:Liposomes; D000808:Angiotensinogen; D000804:Angiotensin II; D000803:Angiotensin I; D012504:Saralasin